Pazár Maldonado B, So A
Department of Rheumatology, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Suisse.
Z Rheumatol. 2012 Feb;71(2):127-36; quiz 137. doi: 10.1007/s00393-012-0961-4.
Gout is an inflammatory arthritis caused by monosodium urate (MSU) crystal deposits in and around the joint. The formation of urinary calculi can also occur in gout, but are less common than arthritis. Gout usually presents with recurrent episodes of joint inflammation, which over time lead to tophus formation and joint destruction. In the last decade, significant advances have been made regarding not only the epidemiology and genetics of gout and hyperuricemia but also the mechanisms of inflammation and treatment of gout. In addition, knowledge concerning the key role of interleukin 1 (IL-1) has provided new therapeutic perspectives. However, the current management of gout is often suboptimal, with many Patienten either not receiving adequate treatment or being unable to tolerate existing treatments. New therapeutic agents provide interesting new options for Patienten with difficult-to-treat gouty arthritis.The English full-text version of this is available at SpringerLink (under "Supplemental").
痛风是一种由单钠尿酸盐(MSU)晶体沉积在关节内及关节周围而引起的炎性关节炎。痛风患者也可能出现尿路结石,但比关节炎少见。痛风通常表现为反复发作的关节炎症,随着时间的推移会导致痛风石形成和关节破坏。在过去十年中,不仅在痛风和高尿酸血症的流行病学和遗传学方面,而且在痛风的炎症机制和治疗方面都取得了重大进展。此外,关于白细胞介素1(IL-1)关键作用的认识提供了新的治疗前景。然而,目前痛风的管理往往不理想,许多患者要么没有得到充分治疗,要么无法耐受现有治疗。新的治疗药物为治疗困难的痛风性关节炎患者提供了有趣的新选择。本文的英文全文版本可在SpringerLink(“补充材料”下)获取。